Oskare Capital
VC Fund
Paris, France
Oskare Capital is a venture capital firm.
- Total investments:
- 9
- Last investment:
- Lead investor:
- 56%
Last updated:
For AI agents: llms.txt
Industries Oskare Capital invests in
Stages Oskare Capital invests in
Countries Oskare Capital invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
2 more contacts available
Round size
- Seed
- $1.2M–$3.4M
- Series A
- $4.7M–$5.9M
Investment Focus
Industry
- Health Care 2 (22%)
- Biotechnology 2 (22%)
- Medical 1 (11%)
- Wellness 1 (11%)
- Biopharma 1 (11%)
Stage
- Seed 2 (22%)
- Series A 2 (22%)
- Pre-Seed 1 (11%)
Country
- Italy 1 (11%)
- Denmark 1 (11%)
- United Kingdom 1 (11%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Jeff Wechsler
Venture Partner
|
Venture Partner | Total investments: 0 | Find email | |
Josh Levy
Operating Partner
|
Operating Partner | Total investments: 0 | Find email | |
Nicola Broughton
Co-Founder and Managing Partner
|
Co-Founder and Managing Partner | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Octarine Bio
|
Octarine Bio is a synthetic biology company that produces superior cannabinoids for the pharmaceutical industry. | $5.9M / Series A / Jan 22, 2026 | |
|
Octarine Bio
|
Octarine Bio is a synthetic biology company that produces superior cannabinoids for the pharmaceutical industry. | $4.7M / Series A / Nov 08, 2023 | |
Leva Clinic
|
Leva Clinic offers health care services for people with chronic pain. Their medical services include back pain, cancer pain, endometriosis, facial pain, fibromyalgia, joint pain, knee pain, multiple sclerosis, sciatica, and so on. | $3.4M / Seed / Nov 04, 2022 | |
|
Leva Clinic
|
Leva Clinic offers health care services for people with chronic pain. Their medical services include back pain, cancer pain, endometriosis, facial pain, fibromyalgia, joint pain, knee pain, multiple sclerosis, sciatica, and so on. | $3.4M / Seed / Nov 04, 2022 | |
|
Octarine Bio
|
Octarine Bio is a synthetic biology company that produces superior cannabinoids for the pharmaceutical industry. | $2M / Seed / Sep 20, 2022 | |
Herbolea Biotech
|
Herbolea is a biotech company envisioning the use of innovative, green technologies to obtain safe, high-quality and low-cost natural products. Herbolea’s patented Bio-refining Platform generates unique products from highly therapeutic potential botanicals in a safe, environmentally friendly, and cost-competitive way. The company has signedlicensing agreements with pharmaceutical companies in Canada, Colombia, Germany, Italy and Zimbabwe. The company has assembled a team of highly seasoned executives with a proven track record in building successful companies. | $5.8M / Series A / Oct 26, 2021 | |
|
Octarine Bio
|
Octarine Bio is a synthetic biology company that produces superior cannabinoids for the pharmaceutical industry. | $1.2M / Seed / Mar 11, 2021 | |
|
Octarine Bio
|
Octarine Bio is a synthetic biology company that produces superior cannabinoids for the pharmaceutical industry. | $1.8M / Seed / Nov 12, 2020 | |
|
Octarine Bio
|
Octarine Bio is a synthetic biology company that produces superior cannabinoids for the pharmaceutical industry. | Pre-Seed |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Oskare Capital invest in?
Oskare Capital invests primarily in Health Care, Biotechnology and Medical startups, most often at Seed and Series A stage. Most of the 9 investments tracked by Shizune back companies in Italy. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Oskare Capital's check size?
Oskare Capital typically joins rounds of $1.2M–$3.4M at Seed and $4.7M–$5.9M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Oskare Capital participates in.
How do I contact Oskare Capital?
Public channels for Oskare Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Oskare Capital?
The team at Oskare Capital includes Jeff Wechsler (Venture Partner), Josh Levy (Operating Partner) and Nicola Broughton (Co-Founder and Managing Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
